Egypt-based e-health startup DilenyTech has secured a US$160,000 non-equity grant to expand its AI-enabled platform to improve and expedite breast cancer detection.
Founded in 2018, DilenyTech aims to revolutionise breast cancer screening and diagnostic workflow by providing innovative AI-based assistance for more accurate detection and expedited reporting.
The startup develops solutions for medical imaging analysis, breast cancer risk assessment, and structured reporting in several medical applications, and has provided its services to top-tier international health-tech companies with active users in three different continents.
It now plans to scale operations after receiving US$160,000 grant capital from the Information Technology Academia Collaboration (ITAC) programme, which is affiliated with Egypt’s Information Technology Industry Development Agency (ITIDA). This comes a few months after DilenyTech was awarded a US patent for a novel AI-enabled image analysis technology.
“Thousands of healthcare professionals can access our online platform anytime, anywhere. This shall reduce patients’ suffering due to long waiting time as well as inaccurate diagnosis,” said Dr Ahmed Ehab Mahmoud, founder and chief innovation officer of DilenyTech.
